Viable CAR T-cells remain detectable in cerebrospinal fluid in patients with grade ≥3 ICANS despite corticosteroid therapy - Takeaways - MDSpire

Viable CAR T-cells remain detectable in cerebrospinal fluid in patients with grade ≥3 ICANS despite corticosteroid therapy

  • By

  • Alexander Casimir Angleitner

  • Markus Maulhardt

  • Gerald Wulf

  • Judith Büntzel

  • June 11, 2026

  • 0 min

Share

  • 1

    This study analyzed 13 patients with grade ≥3 ICANS after CAR T-cell therapy, revealing viable CAR T-cells in cerebrospinal fluid (CSF).

  • 2

    Viable CAR T-cells were detected in all 11 evaluable CSF samples, with a median viability of 75%, despite high-dose corticosteroid treatment.

  • 3

    CAR T-cells remained detectable in CSF for up to 98 days post-infusion, indicating prolonged survival in the central nervous system.

  • 4

    Routine CSF analyses showed elevated protein and albumin levels, suggesting blood–CSF barrier disruption in patients with ICANS.

  • 5

    This research is the first to demonstrate the viability of CAR T-cells in CSF, highlighting the need for further functional studies.

Original Source(s)

Viable CAR T-cells remain detectable in cerebrospinal fluid in patients with grade ≥3 ICANS despite corticosteroid therapy

  • by Alexander Casimir Angleitner, Markus Maulhardt, Gerald Wulf, Judith Büntzel

  • June 11, 2026

Related Content

The unheard pain: why patient-related barriers remain the weakest link in cancer pain management

Precision Diagnostics and the ADC Revolution

Antibody-drug conjugates are transforming cancer care, but their success depends on more precise, sensitive, and data-driven diagnostics

  • June 10, 2026

  • 15 min
Epigallocatechin-3-gallate suppressed breast oncogenesis via the miR-27a/Wnt/β-catenin pathway axis